After EMPA-REG OUTCOME and LEADER: Already a „New Era“ in Therapy of Type 2 Diabetes?

Abstract

Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.

Key words

empagliflozin - liraglutid - cardiovascular effects - new era of treatment? - add-on to metformin?

• References

• 1 Tucker M. „New era“ of type 2 diabetes treatment as LEADER unveiled?. http://www.medscape.com/viewarticle/864729_print
• 2 Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med September 17 2015; DOI: 10.1056/NEJMoa1504720.
• 3 Marso SB et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med June 13 2016; DOI: 10.1056/NEJMoa1603827.
• 4 Schatz H. Empagliflozin (Jardiance^®), ein SGLT2-Hemmer, verringert signifikant kardiovaskuläre Ereignisse bei Hochrisiko-Typ-2 Diabetes-Patienten. www.blog.endokrinologie.net 18 September 2016
• 5 Schatz H. Liraglutid senkt kardiovaskuläre Ereignisse bei Typ-2-Diabetes: die Zahlen der LEADER-Studie. www.blog.endokrinologie.net 17 June 2016
• 6 Eckel RH In: Miriam Tucker: „New era“ of type 2 diabetes treatment as LEADER unveiled?. http://www.medscape.com/viewarticle/864729_print
• 7 Joshua J. Fenton: Clinicians Should Think Twice Before Prescribing DPP-4 Inhibitors for Diabetes. Evidence Based Medicine 2016; 21: 81-82
• 8 Wysham CH et al. Cardiovascular outcomes with antihyperglycemic therapy: Past, present and future impact on practice. http://www.medscape.org/viewarticle/864239?src=mkmcmr_driv_s…
• 9 Rados DV et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016; Apr 13: e1001992 Published online 2016 Apr 12. DOI: 10.1371/journal.pmed.1001992. Corrected: see PLoS Med. 2016 June 24; 13 (6): e1002091